Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 4/20 | 0.36 |
| ▸ | PPARD | Q03181 | 2/20 | 0.36 |
| ▸ | PPARA | Q07869 | 2/20 | 0.36 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.36 |
| ▸ | ITGAV | P06756 | 2/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.34 |
| ▸ | ADA | P00813 | 1/20 | 0.34 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.33 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2003846 | 0.83 | ITGB3 (0.38) | PPARGPPARDPPARAITGB3ITGAV | |
| SCHEMBL2001593 | 0.77 | PPARD (0.53) | PPARGPPARDPPARA | |
| SCHEMBL2006474 | 0.77 | PPARD (0.53) | PPARGPPARDPPARA | |
| SCHEMBL1995408 | 0.77 | ITGB3 (0.41) | PPARGPPARDPPARAITGB3ITGAV | |
| SCHEMBL2004565 | 0.74 | PPARG (0.55) | PPARGPPARDPPARA | |
| SCHEMBL2000733 | 0.71 | ITGB3 (0.42) | ITGB3ITGAV | |
| SCHEMBL1995447 | 0.70 | SRD5A2 (0.52) | KMT2A | |
| SCHEMBL1995445 | 0.70 | SRD5A2 (0.52) | KMT2A | |
| SCHEMBL12568444 | 0.70 | PPARD (0.37) | PPARGPPARDPPARAITGB3ITGAV | |
| SCHEMBL2000111 | 0.69 | PPARG (0.40) | PPARGPPARDPPARAITGB3ITGAV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964622-B2 | Indole acetic acid derivatives and their use as pharmaceutical agents | BAYER HEALTHCARE LLC (US) | 2011-06-21 | — | — | US | disclosed |
| US-7964622-B2 | Indole acetic acid derivatives and their use as pharmaceutical agents | BAYER HEALTHCARE LLC (US) | 2011-06-21 | — | — | US | disclosed |
| US-7964622-B2 | Indole acetic acid derivatives and their use as pharmaceutical agents | BAYER HEALTHCARE LLC (US) | 2011-06-21 | — | — | US | disclosed |
| US-20090298854-A1 | Indole acetic acid derivatives and their use as pharmaceutical agents | MA XIN | 2009-12-03 | — | — | US | disclosed |
| US-20090298854-A1 | Indole acetic acid derivatives and their use as pharmaceutical agents | MA XIN | 2009-12-03 | — | — | US | disclosed |
| US-20090298854-A1 | Indole acetic acid derivatives and their use as pharmaceutical agents | MA XIN | 2009-12-03 | — | — | US | disclosed |
| US-7592361-B2 | (5-{3-[4-(4,5,6,7-tetrahydro-benzooxazol-2-yl)-phenoxy]-propoxy}-indol-1-yl)-acetic acid; diabetes, obesity, hyperlipidemia, and atherosclerotic disease | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| US-7592361-B2 | (5-{3-[4-(4,5,6,7-tetrahydro-benzooxazol-2-yl)-phenoxy]-propoxy}-indol-1-yl)-acetic acid; diabetes, obesity, hyperlipidemia, and atherosclerotic disease | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| US-7592361-B2 | (5-{3-[4-(4,5,6,7-tetrahydro-benzooxazol-2-yl)-phenoxy]-propoxy}-indol-1-yl)-acetic acid; diabetes, obesity, hyperlipidemia, and atherosclerotic disease | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| US-20060264486-A1 | Indole acetic acid derivatives and their use as pharmaceutical agents | BAYER HEALTHCARE LLC | 2006-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298854-A1 | Indole acetic acid derivatives and their use as pharmaceutical agents | IDO1, IDO2, AADAT | PPARG 347/4885PPARD 452/4885PPARA 243/4885 |
| US-20060264486-A1 | Indole acetic acid derivatives and their use as pharmaceutical agents | IDO1, IDO2, AADAT | PPARG 347/4885PPARD 452/4885PPARA 243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.